Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · First Tracks Biotherapeutics, Inc. (TRAX)

First Tracks reports Q3 2026 net loss of $31.4 million, down from $41.9 million a year earlier

Positive Impact 3 of 5 earnings Written later

First Tracks Biotherapeutics reported third-quarter 2026 results in an 8-K filing that attaches its earnings press release. The company reported a net loss of $31.4 million, or $0.88 per share, compared with $41.9 million, or $1.50 per share, in the same quarter of 2025, as research and development and general and administrative expenses both declined. Shareholders also received a business update that includes a $200 million private placement completed in October 2026, which the company said brings pro forma cash to $343 million.

Key points

  • Q3 2026 net loss was $31.4 million ($0.88 per share), versus $41.9 million ($1.50 per share) in Q3 2025.
  • Research and development expense was $23.8 million for Q3 2026, down from $33.3 million a year earlier.
  • Cash, cash equivalents and investments were $155.6 million at Sept. 30, 2026; pro forma cash is $343 million after the $200 million private placement.
  • For the nine months, the net loss was $115.2 million, compared with $131.5 million, while general and administrative expense rose to $37.1 million from $28.2 million.

The filing

CompanyFirst Tracks Biotherapeutics, Inc. (TRAX)
Form8-K, current report
Filed with the SECNov 3, 2026, 4:18 PM ET
Accession number0001193125-26-445405

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.